ZOETIS HISTORY With more than 65 years of experience and a singular focus on animal health, Zoetis is working every day to better understand and address the real-world challenges faced by those who raise and care for animals. This timeline offers an overview of major milestones over the last six decades, including significant product developments, business acquisitions and corporate recognitions. YEAR PRODUCT INNOVATION AND CORPORATE GROWTH . Researchers at Pfizer, the former parent company of Zoetis, 1950 discovered Terramycin® (oxytetracycline), which is an antibiotic shown to be effective against more than 100 different infectious organisms. It continues to be an effective medicine in protecting the health of livestock today. Pfizer established a dedicated Animal Agriculture division, renamed 1952 Pfizer Animal Health in 1988, which became Zoetis in 2013. Launched Liquamycin® LA 200, a product that can treat 1980 several cattle diseases in one single injection. Launched Dectomax®, an innovative broad-spectrum 1993 parasiticide that continues to be a best-selling product today. Pfizer acquired SmithKline Beecham’s animal health division 1995 (previously Norden Laboratories), and entered the vaccine and small-animal businesses, thereby securing a place in the field of companion animal care. Launched Rimadyl®, the first non-steroidal anti-inflammatory 1997 medicine for dogs, as well as Clavamox®, an anti-infective medicine for dogs and cats. Launched Revolution®, the first FDA-approved topical medicine that protects against heartworm and flea infestations, kill fleas, and treat 1999 and control ear mites. Pfizer acquired Pharmacia Corporation, which allowed the 2003 company to add a variety of animal health assets to its cattle product portfolio. Pfizer acquired CSL Animal Health, which strengthened the company’s global pipeline and portfolio in Australia and New Zealand. Established dedicated R&D headquarters in Kalamazoo, Michigan. Launched Draxxin®, a novel antibiotic for livestock that delivers 2004 a full course of therapy in a single dose. YEAR PRODUCT INNOVATION AND CORPORATE GROWTH . Launched Convenia®, the first anti-infective for the treatment of 2006 common bacterial skin infections in cats that provides an entire course of treatment in a single injection. Pfizer acquired Embrex Inc. and expanded into the poultry devices 2007 and vaccines business. Launched Cerenia®, the first antiemetic therapy approved to treat vomiting in dogs and cats and prevent vomiting due to motion sickness in dogs. Pfizer acquired Catapult Genetics (Australia and New Zealand) and 2008 Bovigen LLC (U.S.) and gained expertise in animal genetics, including DNA technology and gene markers for livestock producers. Launched Palladia®, the first drug to be approved by the FDA 2009 for treating mast cell cancer tumors in dogs. Pfizer acquired Wyeth, along with Fort Dodge Animal Health, which brought key brands such as ProHeart® for dogs, Synovex® for cattle and West Nile Innovator®/Duvaxyn® vaccines for horses, as well as a complementary poultry vaccines business. Pfizer acquired Microtek International Inc. and entered into vaccines 2010 for aquaculture. Pfizer acquired Synbiotics Corporation and entered into animal diagnostics. Pfizer acquired King Pharmaceuticals, Inc., along with Alpharma, 2011 which strengthened the company’s position in the poultry business with a medicated feed additives business, and further strengthened the company’s position in the cattle and swine business. Established vaccine manufacturing capabilities in China through formation of the Jilin Pfizer Guoyuan joint venture. Launched Improvest® in the United States, the only product to reduce boar taint in male pigs as an alternative to surgical castration. YEAR PRODUCT INNOVATION AND CORPORATE GROWTH . Pfizer announced that its Animal Health business would become a 2012 separate company called Zoetis (zō-EH-tis). Zoetis celebrated its Initial Public Offering (IPO), becoming the 2013 world’s leading publicly traded animal health company. Announced approval of Apoquel® in the United States, the European Union and New Zealand. In the United States, Apoquel is indicated for the control of pruritus associated with allergic dermatitis and the control of atopic dermatitis in dogs at least 12 months of age. Opened new global headquarters in Florham Park, New Jersey, USA. Became a member of the S&P 500. Completed separation from Pfizer and became a fully independent animal health company. Announced the approval of Rui Lan An™, a specialized vaccine to help control the highly pathogenic porcine reproductive and respiratory syndrome (HP PRRS) in mainland China. Rui Lan An is the first vaccine to result from the company's joint venture in China in 2011. Launched Apoquel® in the U.S. and Europe, which quickly 2014 became a blockbuster drug and advanced dermatology treatment options for dogs. Conducted first Annual Meeting of Shareholders in Short Hills, New Jersey. Received approval of Versican® Plus across the European Union. This combination vaccine for dogs contains nine vaccine antigens helping to protect against ten key canine diseases in one vaccine dose. Granted a conditional license in the U.S. for a vaccine to help fight porcine epidemic diarrhea virus (PEDv). Named one of Working Mother Magazine’s “100 Best Companies for Working Mothers.” (2014, 2015, 2016, 2017 and 2018) . Held inaugural Investor Day at the New York Stock Exchange. Announced the reintroduction of Zoamix® a versatile synthetic anticoccidial for the prevention and control of coccidiosis in broilers and turkeys. YEAR PRODUCT INNOVATION AND CORPORATE GROWTH . Acquired the animal health assets of Abbott, which expanded 2015 the Zoetis companion animal product portfolio to bring veterinarians solutions for pain, diabetes and oncology. Acquired KL Products, Inc., a leader in automation systems for the poultry industry. Granted USDA conditional license for Canine Atopic Dermatitis Immunotherapeutic, later introduced and launched as Cytopoint®, a first-of-its-kind antibody therapy to help reduce clinical signs associated with atopic dermatitis and allergic dermatitis in dogs. Enhanced Manufacturing and Supply network with expansions in Lincoln, Nebraska and Suzhou, China. Acquired PHARMAQ, the global leader in vaccines and innovation for health products in aquaculture. Received European Commission approval (2015) and U.S. 2016 Food & Drug Administration approval (2016) for Simparica®, a once-monthly chewable flea and tick medication for dogs. PHARMAQ business in Chile launched Alpha Ject® LiVac® SRS vaccine for salmon, the first attenuated live vaccine against Salmon Rickettsia Syndrome. Expanded Vanguard® vaccine franchise for dogs with licenses granted by USDA for a new Vanguard B oral vaccine and three new Vanguard Rapid Resp Intranasal vaccines, making Zoetis the only manufacturer to offer oral, intranasal and injectable options for vaccinating against Bordatella bronchiseptica. Broadened disease prediction solutions with launch of genomic test Clarifide® Plus in the U.S. Named one of America’s Best Midsize Employers by Forbes Magazine. (2016, 2017 and 2018) . Acquired Scandinavian Micro Biodevices, a pioneer in developing and manufacturing microfluidic “lab on a chip” diagnostic analyzers and tests for veterinary point-of-care services. Established new global headquarters in Parsippany, New Jersey, USA. Received U.S. approval for Cytopoint®, the first veterinary monoclonal antibody to help control clinical signs of atopic dermatitis and allergic dermatitis in dogs. (EU approval in 2017) YEAR PRODUCT INNOVATION AND CORPORATE GROWTH . Received European Commission approval for Stronghold® 2017 Plus, a topical combination of parasiticides for cats. (This product, also known as Revolution® Plus, was approved in the U.S., Japan and Canada in 2018.) . Acquired Nexvet for monoclonal antibody therapies for companion animals. Debuted first-ever direct-to-consumer campaigns in the U.S. and Brazil. Announced program to build better animal health productivity in Africa: African Livestock Productivity and Health Advancement (A.L.P.H.A.) initiative. Acquired full ownership of Zoetis Jilin operations in China. Celebrated fifth year as the leading global animal health 2018 company. Began construction of new vaccine manufacturing and R&D facilities in Suzhou, China. Announced collaboration with Regeneron to research antibody therapies for use in animal health. Received market approvals of Fostera® Gold PCV MH and Suvaxyn® Circo for pigs. Acquired Smartbow, which paves the way for precision dairy farming and early disease intervention through herd health monitoring technology. Acquired Abaxis, a leading global provider of veterinary point-of-care diagnostic instruments and tests. Launched Core EQ Innovator® in the U.S., the first and only vaccine to help protect horses from all five core equine diseases in one injection. April 1, 2019 .